Inhalation Sciences installs first DissolvIt[®][ ]module at Swiss-based laboratory of global corporation
Inhalation Sciences (ISAB) has successfully installed its first ever commercial version of the in vitro DissolvIt[®] module at the Swiss laboratory of a long-term ISAB customer. The module was the first of three shipments that were announced and sent to customers in March just before strict Covid-19 restrictions came into force in many countries worldwide. CEO Manoush Masarrat: “We aim to hit the ground running now that laboratory restrictions in many locations are easing”.
From its commercial launch in spring 2020, demand for DissolvIt® has been strong. Three modules were shipped to three customers in just a couple of weeks following the launch. However, the installations where stalled as Covid-19 lockdown and restrictions on access to laboratories were implemented around the globe. Now, as the restrictions have started to ease up and laboratories are slowly reopening, a team of ISAB representatives has successfully installed the first DissolvIt® module at the customer’s site in Switzerland. In addition to customers now being able to access DissolvIt® at their own laboratories, the disposable sales for each DissolvIt® is estimated to €20 000 annually.
ISAB CEO Manoush Masarrat: “The original order for this module was the result of a successful collaboration between the client and Inhalation Research Services. Given the predictive and precise data delivered, they decided to have a DissolvIt® module in-house. This is why it is so crucial that our systems are up and running in client’s labs. The more data our clients are producing and publishing from our systems, the higher demand for our products and services. We plan additional installations now as travel and laboratory restrictions ease.”
About DissolvIt®
The in vitro simulation module DissolvIt® is seen by many in the inhalation industry as the first tool to show credible, predictive In Vitro-In Vivo Correlated (IVIVC) data. Predictive, preclinical IVIVC data reduces risk, eliminates error and accelerates drug development early on. DissolvIt® also achieves 3R goals by reducing, refining, or replacing the number of animals needed for preclinical lung research. DissolvIt® delivers:
- Dissolution and absorption data for ranking of candidate drugs and comparison of generic candidates versus reference drugs
- Absorption profiles with Cmax and Tmax resembling clinical absorption profiles
- Light microscope photos and/or video of real-time dissolution before/during dissolution
Read more about DissolvIt®
DissolvIt® and Inhalation Research Services
DissolvIt® - five key features in market launch
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153
Press release in PDF format